Q1 FY27: Revenue up 55% on JB Pharma merger; PAT rises just 3%

Revenue Growth 20pctEbitda Margin ExpansionResults RestatedExceptional ItemResults View source PDF Explain this filing

TORNTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.1%Reaction day

₹4890.00

prior close

₹4948.00

announcement price

After-mkt

timing

Nifty 100market+0.5%+4.6% vs market

Pharmaceuticals peers, median of 164sector+0.1%+5.0% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty 100 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.7

15m

-0.4

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.1+0.5+4.6+0.1+5.0

Next day

+3.3+2.0+1.3+1.1+2.2

+2.9+1.4+1.5+1.0+1.8

+2.0+1.5+0.6+1.1+1.0

+1.3+1.5-0.2+1.2+0.2

+1.2+1.4-0.2+1.5-0.3

-0.1+1.0-1.2+2.3-2.4

15d

+0.1+0.1+0.0+1.3-1.2

+3.6-0.5+4.1+2.0+1.6

-1.8-6.4+4.6+3.2-5.0

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Torrent Pharma Q1 FY27 consolidated revenue rose 55% YoY to Rs 4,921 cr, lifted by JB Pharma acquisition. Base business grew 17% to Rs 3,720 cr. Op EBITDA up 61% at Rs 1,664 cr, margin at 33.8%. PAT rose just 3% to Rs 566 cr, margin fell to 11.5% from 17.2% on higher finance and depreciation costs. JB Pharma merger via amalgamation effective Jan 21, 2026. 4.19 cr new shares allotted on July 20. Exceptional items of Rs 21 cr include Rs 19 cr fire-related inventory write-off at JB Pharma warehouse. No auditor qualification.

Likely market impact

Strong topline from JB Pharma merger; bottomline muted despite 61% EBITDA growth. Watch margin trajectory and integration costs post-merger.